These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 25000314

  • 1. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
    Kim S, Abou-Alfa GK.
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):36-41. PubMed ID: 25000314
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Signaling pathways in hepatocellular carcinoma.
    Sia D, Villanueva A.
    Oncology; 2011 Jan; 81 Suppl 1():18-23. PubMed ID: 22212931
    [Abstract] [Full Text] [Related]

  • 5. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Jan; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 6. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 7. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb 01; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 8. Novel molecular therapies in hepatocellular carcinoma.
    Faivre S, Bouattour M, Raymond E.
    Liver Int; 2011 Jan 01; 31 Suppl 1():151-60. PubMed ID: 21205154
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
    Gnoni A, Licchetta A, Memeo R, Argentiero A, Solimando AG, Longo V, Delcuratolo S, Brunetti O.
    Medicina (Kaunas); 2019 Nov 21; 55(12):. PubMed ID: 31766556
    [Abstract] [Full Text] [Related]

  • 11. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.
    Gao J, Inagaki Y, Song P, Qu X, Kokudo N, Tang W.
    Pharmacol Res; 2012 Jan 21; 65(1):23-30. PubMed ID: 22138044
    [Abstract] [Full Text] [Related]

  • 12. Targeting tyrosine kinase receptors in hepatocellular carcinoma.
    Muntané J, De la Rosa AJ, Docobo F, García-Carbonero R, Padillo FJ.
    Curr Cancer Drug Targets; 2013 Mar 21; 13(3):300-12. PubMed ID: 23016985
    [Abstract] [Full Text] [Related]

  • 13. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep 21; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 14. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 15. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL, Salem R.
    J Vasc Interv Radiol; 2013 Aug 01; 24(8):1123-34. PubMed ID: 23562168
    [Abstract] [Full Text] [Related]

  • 16. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX.
    Expert Rev Anticancer Ther; 2008 Apr 01; 8(4):499-505. PubMed ID: 18402516
    [No Abstract] [Full Text] [Related]

  • 17. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS.
    Semin Liver Dis; 2013 Feb 01; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [Abstract] [Full Text] [Related]

  • 18. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 01; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 19. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
    Ibrahim N, Yu Y, Walsh WR, Yang JL.
    Oncol Rep; 2012 May 01; 27(5):1303-11. PubMed ID: 22323095
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.